AROVELLA THERAPEUTIC ORDINARY (ALA) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
KalkineWhy Are Investors Watching (ASX:ALA) in the ASX Smallcap Rally?
Highlights Market focus shifts toward clinical and commercial evidence Funding cycles and execution timelines under closer review Smallcap sentiment shaped by broader ASX rotation signals ASX smallcap health-tech attention is being driven by shifting sentiment, funding conditions, and commercial validation signals across the broader equity market landscape. The discussion around health-tech small-cap proof has re-emerged as market participants reassess h...
Turtle to Clinical Advisory Board&Fiorenza Lead Investigator
other announcement
Arovella Leadership Shift Draws Attention on Clinical Focus
Highlights Leadership transition announced at Arovella Therapeutics Clinical development strategy remains in focus Board signals continuity during transition phase Arovella Therapeutics has announced a leadership transition as the company continues advancing its clinical ambitions and broader biotechnology strategy within the Australian healthcare sector. Australian biotechnology company Arovella Therapeutics (ASX:ALA) has entered a new phase following the appointment of an acting chief...
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Notification regarding unquoted securities - ALA
other announcement
Notice received under section 249D of the Corporations Act
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
ALA files IND with the U.S. FDA for phase 1 clinical trial
other announcement
Appointment of Dr Andrew Nash as Non-Executive Director
other announcement
Change of Director's Interest Notice x2
director_dealing announcement
Notification regarding unquoted securities - ALA
other announcement